Agent for Applying to Mucosa and Method for the Production Thereof
OwnerKenji Miyamoto, Katsuya Takahashi +1inventors
InventorsKenji Miyamoto, Katsuya Takahashi, Yuuji Shimojima
Life of this patent
Estimating the term…
Abstract
An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
Claims36
An agent for applying to mucosa containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
An agent for applying to mucosa containing glycosaminoglycan into which Ph-CH═CH—COO—(CH2)m—NH;
- Ph-CH═CH—COO—CH2—(OCH2)n—NH;
- Ph-CH═CH—CONH—(CH2)m—NH;
- Ph-CH═CH—CONH—CH2—(OCH2)n—NH;
- Ph-CH═CH—COO—(CH2)m—O;
- Ph-CH═CH—COO—CH2—(OCH2)n—O;
- Ph-CH═CH—CONH—(CH2)m—O;
- Ph-CH═CH—CONH—CH2—(OCH2)n—O;
- CH3—(CH2)1—COO-Ph-COHN—(CH2)m—NH or CH3—(CH2)1—COO-Ph-CONH—CH2—(OCH2)n—NH (wherein Ph represents phenyl group, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) is introduced, as the active ingredient.
An agent for applying to mucosa containing glycosaminoglycan having a repeat structure of a structural unit represented by the following formula, as a basic skeleton:
- wherein R represents R1 or R2;
- Ac represents an acetyl group;
- R1 represents ONa or OH;
- R2 represents Ph-CH═CH—COO—(CH2)m—NH—;
- Ph-CH═CH—COO—CH2—(OCH2)n—NH—;
- Ph-CH═CH—CONH—(CH2)m—NH—;
- Ph-CH═CH—CONH—CH2—(OCH2)n—NH—;
- Ph-CH═CH—COO—(CH2)m—O—;
- Ph-CH═CH—COO—CH2—(OCH2)n—O—;
- Ph-CH═CH—CONH—(CH2)m—O—;
- Ph-CH═CH—CONH—CH2—(OCH2)n—O—;
- CH3(CH2)1—COO-Ph-CONH—(CH2)m—NH—;
- or CH3(CH2)1—COO-Ph-CONH—CH2—(OCH2)n—NH—;
- (wherein Ph represents phenyl, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) as a basic skeleton, wherein the ratio of the above structural unit wherein R represents R2 is 5 to 30% in molar equivalent relative to the disaccharide repeat unit in molar equivalent of the glycosaminoglycan.
A method for applying to mucosa an agent containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
A method for applying to mucosa an agent containing glycosaminoglycan into which Ph-CH═CH—COO—(CH2)m—NH;
- Ph-CH═CH—COO—CH2—(OCH2)n—NH;
- Ph-CH═CH—CONH—(CH2)m—NH;
- Ph-CH═CH—CONH—CH2—(OCH2)n—NH;
- Ph-CH═CH—COO—(CH2)m—O;
- Ph-CH═CH—COO—CH2—(OCH2)n—O;
- Ph-CH═CH—CONH—(CH2)m—O;
- Ph-CH═CH—CONH—CH2—(OCH2)n—O;
- CH3—(CH2)1—COO-Ph-COHN—(CH2)m—NH or CH3—(CH2)1—COO-Ph-CONH—CH2—(OCH2)n—NH (wherein Ph represents phenyl group, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) is introduced, as an active ingredient.
A method for applying to mucosa an agent containing glycosaminoglycan having a repeat structure of a structural unit represented by the following formula, as a basic skeleton:
- wherein R represents R1 or R2;
- Ac represents an acetyl group;
- R1 represents ONa or OH;
- R2 represents Ph-CH═CH—COO—(CH2)m—NH—;
- Ph-CH═CH—COO—CH2—(OCH2)n—NH—;
- Ph-CH═CH—CONH—(CH2)m—NH—;
- Ph-CH═CH—CONH—CH2—(OCH2)n—NH—;
- Ph-CH═CH—COO—(CH2)m—O—;
- Ph-CH═CH—COO—CH2—(OCH2)n—O—;
- Ph-CH═CH—CONH—(CH2)m—O—;
- Ph-CH═CH—CONH—CH2—(OCH2)n—O—;
- CH3—(CH2)1—COO-Ph-CONH— (CH2)m—NH—;
- or CH3—(CH2)1COO-Ph-CONH—CH2—(OCH2)n—NH—;
- (wherein Ph represents phenyl, m and n represent integers of 1 to 18, respectively, and 1 represents 0 or an integer of 1 to 18) as a basic skeleton, wherein the ratio of the above structural unit wherein R represents R2 is 5 to 30% in molar equivalent relative to the disaccharide repeat unit in molar equivalent of the glycosaminoglycan.
A method for the treatment of a mucosal disorder comprising applying to mucosa an agent containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
A method for the prevention of a corneal disorder due to ultraviolet rays comprising applying to mucosa eye drops containing glycosaminoglycan into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
Dependencies are inferred from the claim text.